Poster

Metabolic, biochemical, histological, and transcriptomic effects of semaglutide in the GAN diet-induced and biopsy-confirmed ob/ob mouse model of NASH

Background & Aim:
The glucagon-like peptide-1 (GLP-1) analogue semaglutide, currently approved for the treatment of type 2 diabetes and obesity, is in advanced clinical development for non-alcoholic steatohepatitis (NASH).

In line with clinical findings, semaglutide has been shown to improve parameters of NASH, including the NAFLD Activity Score, in the GAN DIO-NASH mouse model.

The present study aimed to evaluate the metabolic, biochemical, histological, and transcriptomic effects of 10 weeks of semaglutide treatment in the GAN ob/ob-NASH mouse model with progressive fibrosis.

Subjects

GAN ob/ob-MASH mouse Mouse Body weight Blood biochemistry Bioinformatics Metabolic dysfunction-associated steatohepatitis GLP-1 receptor Histopathology score Image analysis Liver biopsy Liver morphometry Next-generation sequencing RNA sequencing

Share this page

Resource Library

Related resources

Semaglutide exerts anti-tumor action in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC

Mouse models of nonalcoholic steatohepatitis in preclinical drug development

Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis

Clinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650